



# GLAND PHARMA LIMITED

May 4, 2022

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

**Sub: Press Release – Launch of Bortezomib for Injection through our partner in the US Market**

Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find the attached press release for the captioned subject.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



**Sampath Kumar Pallerlamudi**  
**Company Secretary and Compliance Officer**

**Regd. Office:**

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**

Plot No. 11 & 84, TSIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999



## **Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial launched in the US Market**

**Hyderabad, May 04, 2022:** Gland Pharma Limited (BSE: 543245 | NSE: GLAND), a generic injectable focused pharmaceutical company, earlier this week, through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market. It is the bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade® for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc.

Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma.

Velcade has a market size of USD 1,172 million for the twelve months ending March 2022, according to IQVIA.

Gland Pharma's partner has received the ANDA approval for the product from U.S. Food & Drug Administration (US FDA). Gland Pharma is manufacturing and supplying this product to its partner for the US market.

### **About Gland Pharma Limited (BSE: 543245, NSE: GLAND)**

Gland Pharma was established in 1978 in Hyderabad, has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: [www.glandpharma.com](http://www.glandpharma.com)

### **Contacts:**

Sampath Kumar Pallerlamudi  
Company Secretary and Compliance Officer  
investors@glandpharma.com

Sumanta Bajpayee  
Vice President – Finance & Investor Relations  
sumanta.bajpayee@glandpharma.com

*This release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Gland Pharma Limited, its directors and any of the affiliates or employee is under no obligation to, and expressly assume any obligation to update any particular forward-looking statement contained in this release.*